In the News

BASEPAWS + MWI

Basepaws unveils new genomic screening tools for veterinary teams

July 28, 2022
dvm360 Staff - Read the dvm360 article here

Encourages customized proactive care for potentially better patient outcomes

figure imageBasepaws Inc, a Zoetis company and pioneer in pet care genetics, has released a comprehensive portfolio exclusively for veterinary professionals: genetic and oral microbiome screening tools for disease risk.

According to a company release,1 Basepaws’ DNA sequencing offers more detailed and specific insights than the consumer-facing methods. Basepaws Veterinary genetic tests screen for 64 feline health markers and over 210 canine health markers related to known genetic diseases. Plus, Basepaws Veterinary oral microbiome tests examine over 600 relevant oral microbes to assess risk for the most common feline dental disease. The data collected can direct veterinarians and pet owners in choosing yearly wellness programs, routine diagnostic tests, and lifestyle changes based on a pet’s unique genetics.

What’s more, Basepaws is launching exclusively with MWI Animal Health, a distributor of animal health products and services and a subsidiary of AmerisourceBergen, to advance veterinarians’ access to their portfolio of genomic and oral microbiome screening tools.

“The pace of innovation across the animal health industry continues to accelerate. At MWI, we continue to expand our services and enhance our distribution capabilities to ensure veterinarians nationwide have timely and reliable access to products that have the potential to help pets live longer and healthier lives,” said Steve Shell, president of MWI Animal Health.1 “We are excited to work with Basepaws to provide veterinarians efficient access to the company’s new screening tools.”

Read the Basepaws news release here.

LEARN MORE
BASEPAWS + ZOETIS

Zoetis Completes Acquisition of Basepaws, an Innovative Leader in Petcare Genetics, to Strengthen its Portfolio of Precision Animal Health Solutions

June, 22, 2022
 

PARSIPPANY, N.J.--(BUSINESS WIRE)-- Zoetis Inc. (NYSE:ZTS) today announced the completion of its acquisition of Basepaws, a privately held petcare genetics company, which provides pet owners with genetic tests, analytics and early health risk assessments. The genetic insights from Basepaws help pet owners and veterinarians understand an individual pet’s risk for disease and can lead to more meaningful engagements and increased likelihood of early detection and treatment of disease. The acquisition was first announced on June 7th, and financial terms of the transaction were not disclosed.

“When we first met Basepaws CEO Anna Skaya and the team, we were immediately drawn to their passion for pets and the role that genetic testing and data analytics can have in advancing animal care – a purpose that drives us every day,” said Zoetis CEO Kristin Peck. “The addition of Basepaws will enhance our portfolio in the precision animal health space and inform our future pipeline of petcare innovations. Working together, we can continue to provide veterinarians and pet owners with more comprehensive ways to proactively manage the health, wellness and quality of care for their animals.”

READ MORE
RESEARCH

Basepaws seeks participants for feline and canine dermatitis research

The health data from these studies may inform the development of new screening tools, says Basepaws.

dermatitis research cat dog

If you are a veterinary professional in a practice that has a prevalence of feline or canine atopic dermatitis and/or food allergic dermatitis cases, Basepaws welcomes you to join this research effort. The genetic and oral microbiome health data from these studies could potentially inform the development of new screening tools that could change the future of diagnosis and treatment for dogs and cats affected by these debilitating conditions.

Please contact Basepaws directly at science@basepaws.com to participate. You can also visit the Basepaws Research page to learn about additional clinical studies for which the company is currently recruiting.

LEARN MORE
RESEARCH

Basepaws seeks participants for clinical research on GI lymphoma and IBD

 

The importance of research on GI lymphoma and IBD and how to participate in the Basepaws study

figure image

Basepaws is actively seeking veterinary partners to aid in clinical recruitment for its canine and feline GI lymphoma studies to build off of and validate its preliminary citizen science research findings. The company is collaborating on this project with veterinary partners such as Nicole Martell-Moran, DVM, MPH, DABVP (feline), of The Feline Medical Center in Houston, Texas. If you are a veterinary professional in a practice that has a prevalence of feline or canine GI lymphoma and/or IBD cases, Basepaws welcomes the chance to collaborate with you and your team. The genetic and oral microbiome health data from this research could potentially inform the development of new screening tools that more reliably distinguish between GI lymphoma and IBD.

You can contact Basepaws directly at science@basepaws.com to participate. You can also read Basepaws’ blog on GI lymphoma and IBD and visit the Basepaws Research page to learn how to participate in other ongoing clinical studies.

LEARN MORE
DVM360 Article

Bring cat behavior basics into your practice to improve their health and your relationships with cat clients

 
Want happier clients? Make cat behavior basics a routine at your clinic. Here’s how.
figure image
Read at DVM360